Theravance Biopharma (NASDAQ:TBPH) Receives Neutral Rating from BTIG Research

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “neutral” rating reissued by stock analysts at BTIG Research in a research note issued on Thursday, Benzinga reports.

A number of other brokerages have also recently issued reports on TBPH. Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 7th. Weiss Ratings raised shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. HC Wainwright downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Finally, JonesTrading cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. Eight analysts have rated the stock with a Hold rating, According to data from MarketBeat, Theravance Biopharma has a consensus rating of “Hold” and an average price target of $19.40.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $17.03 on Thursday. The company has a market cap of $884.20 million, a PE ratio of 16.86 and a beta of 0.25. The business’s 50 day moving average is $16.97 and its two-hundred day moving average is $16.45. Theravance Biopharma has a 52 week low of $13.08 and a 52 week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The firm had revenue of $20.73 million for the quarter, compared to analyst estimates of $22.49 million. As a group, sell-side analysts expect that Theravance Biopharma will post 1.56 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In other news, major shareholder Eli Samaha sold 273,871 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $17.23, for a total value of $4,718,797.33. Following the sale, the insider owned 9,237,279 shares of the company’s stock, valued at approximately $159,158,317.17. The trade was a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total value of $226,737.42. Following the transaction, the senior vice president directly owned 213,476 shares in the company, valued at approximately $3,635,496.28. The trade was a 5.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 350,011 shares of company stock valued at $6,016,830 over the last quarter. Insiders own 7.65% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TBPH. Squarepoint Ops LLC bought a new position in shares of Theravance Biopharma in the second quarter valued at $302,000. Groupe la Francaise acquired a new stake in shares of Theravance Biopharma during the second quarter worth $510,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Theravance Biopharma during the second quarter valued at $1,071,000. GTS Securities LLC acquired a new position in shares of Theravance Biopharma in the 2nd quarter valued at $430,000. Finally, Hsbc Holdings PLC increased its stake in Theravance Biopharma by 14.4% in the 2nd quarter. Hsbc Holdings PLC now owns 49,428 shares of the biopharmaceutical company’s stock worth $843,000 after purchasing an additional 6,224 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.